Cinnagen

Executive Summary

Cinnagen is an Israeli biotech company pioneering next-generation mRNA therapeutics using a proprietary self-amplifying mRNA (saRNA) platform combined with advanced lipid nanoparticle (LNP) delivery. Founded in 2020, the company targets rare genetic diseases and oncology, aiming to achieve durable protein replacement and robust immuno-oncological responses with reduced dosing frequency. Its saRNA technology enables prolonged antigen expression compared to conventional mRNA, potentially lowering required doses and enhancing efficacy. Cinnagen has raised $120 million to date, reflecting strong investor confidence in its platform and preclinical progress. Currently in the preclinical stage, Cinnagen is advancing a pipeline of saRNA candidates toward clinical development. The company's lead programs focus on rare metabolic disorders and solid tumors, with IND-enabling studies underway. Initial preclinical data have demonstrated durable protein expression and potent anti-tumor immunity in animal models. Cinnagen's scalable manufacturing process and rapid design capabilities position it well for clinical translation. Over the next 12-18 months, key milestones include IND filings for lead indications, potential partnership deals, and additional preclinical efficacy readouts, which could validate the platform's broad applicability and drive significant value inflection.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for Rare Disease Lead Program60% success
• Q3 2026Preclinical Proof-of-Concept Data in Oncology80% success
• H2 2026Strategic Partnership or Licensing Deal40% success